The solution lies in future in-depth research and clinical translation: on one hand, relying on novel biomarkers such as CET, the peripheral blood transcriptome, and circulating tumor DNA to achieve truly individualized dosing and risk stratification; on the other hand, actively developing more selective intervention strategies, including bispecific antibodies targeting CD47/GPC3, regulating immune metabolic checkpoints like MTHFD2, utilizing nanotechnology for targeted delivery as exemplified by AU-siRetn, and intervening in the gut–liver axis immune microenvironment. This evidence concerns the gene GPC3 and neoplasm.